Morgan Joseph Reiterates a 'Buy' on BioMarin Pharmaceutical (BMRN)
BMRN Hot Sheet
Rating Summary:7 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 1
Morgan Joseph reiterates a 'Buy' rating on BioMarin Pharmaceutical (Nasdaq: BMRN), price target $20.
Morgan analyst says, "Although the possibility of additional acquisitions could prevent near-term outperformance, our long-term thesis remains unchanged: We expect BioMarin's top line, driven by four growing drugs, to improve margins over the next few years. We believe that BioMarin will be able to generate one additional drug during the next 5 years to drive the company's margins towards the
average of profitable biotechs."
To see more analyst ratings on BMRN Click Here.
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions.
Morgan analyst says, "Although the possibility of additional acquisitions could prevent near-term outperformance, our long-term thesis remains unchanged: We expect BioMarin's top line, driven by four growing drugs, to improve margins over the next few years. We believe that BioMarin will be able to generate one additional drug during the next 5 years to drive the company's margins towards the
average of profitable biotechs."
To see more analyst ratings on BMRN Click Here.
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions.
You May Also Be Interested In
- Jefferies Analysts Adjust Price Target on hhgregg, Inc. (HGG)
- Not All Chinese Solar Companies a Sell, Hold Trina Solar (TSL)
- Barclays Cuts Price Target and Estimates on NetApp (NTAP); Disappointing Qtr, But There Is Hope
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Morgan JosephSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
